Stocks and InvestingStocks and Investing
Fri, October 11, 2019
Thu, October 10, 2019
Wed, October 9, 2019
Tue, October 8, 2019
Mon, October 7, 2019
Fri, October 4, 2019
Thu, October 3, 2019
Wed, October 2, 2019
Tue, October 1, 2019

Gregory Renza Initiated (ACAD) at Buy and Held Target at $60 on, Oct 1st, 2019


Published on 2024-10-26 16:32:40 - WOPRAI, Gregory Renza
  Print publication without navigation


Gregory Renza of RBC Capital, Initiated "ACADIA Pharmaceuticals Inc." (ACAD) at Buy and Held Target at $60 on, Oct 1st, 2019.

Gregory has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 1 agrees with Gregory's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $28 on, Tuesday, September 3rd, 2019


These are the ratings of the 4 analyists that currently disagree with Gregory


  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $56 on, Monday, September 23rd, 2019
  • Marc Goodman of "SVB Leerink" Upgraded from Hold to Buy and Increased Target to $50 on, Friday, September 13th, 2019
  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy on, Tuesday, September 10th, 2019
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $60 on, Monday, September 9th, 2019